References
Crado PR, Criado RFJ, Avancini JdM, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS)/Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts. Ann Bras Dermatol. 2012;87:435–449.
Whitley RJ. In: Baron S, eds. Medical Microbiology. 4th ed. Galveston, TX: University of Texas Medical Branch at Galveston; Chapter 68; 1996.
Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083–1084.
International Committee on Taxonomy of Viruses. ICTV Master Species List 2011.
Johnson S, Mathews S, Hudnall SD. Human herpesvirus 6 lymphadenitis in drug rash with eosinophilia and systemic symptoms syndrome: a lymphoma mimic. Histopathology. 2017;70:1166–1170.
Ferrero NA, Pearson KC, Zedek DC, Morrell DS. Case report of drug rash with eosinophilia and systemic symptoms demonstrating human herpesvirus-6 reactivation. Pediatr Dermatol. 2013;30:608–613.
Isaacson E, Glaser CA, Forghani B, Amad Z, et al. Evidence of human herpesvirus-6 infection in 4 immunocompetent patients with encephalitis. Clin Infect Dis. 2005;40:890–893.
Challoner PB, Smith KT, Parker JD, MacLeod DL, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA. 1995;92:7440–7444.
Alvarez-Lafuente R, De las Heras V, BartoloméM Picazo JJ, Arroy R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol. 2004;61:1523–1527.
Härmä M, Höckerstedt K, Lautenschlager I. Human herpesvirus-6 and acute liver failure. Transplantation. 2003;76:536–539.
Charnot-Katsikas A, Baewer D, Cook L, David MZ. Fulminant hepatic failure attributed to infection with human herpesvirus 6 (HHV-6) in an immunocompetent woman: a case report and review of the literature. J Clin Virol. 2016;75:27–32.
Picard D, Janela B, Descamps V, D’Incan M, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2:46ra62. https://doi.org/10.1126/scitranslmed.30011.
Tuqan W, Lee S, Hanson J, McCarthy D. Carbamazepine-Associated Hypersensitivity Colitis. Dig Dis Sci. 2018;63:334–337. https://doi.org/10.1007/s10620-017-4881-7.
Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–1778.
Blumberg BM, Mock DJ, Powers JM, Ito M, et al. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J Clin Virol. 2000;16:159–176.
Fotheringham J, Akhyani N, Vortmeyer A, Donati D, et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. Infect Dis. 2007;195:450–454.
Flamand L, Gravel A, Boutolleau D, Alvarez-Lafuente R, et al. Multicenter comparison of PCR assays for detection of human herpesvirus 6 DNA in serum. J Clin Microbiol. 2008;46:2700–2706.
Traylen CM, Patel HR, Fondaw W, Mahatme S, et al. Virus Reactivation: a panoramic view in human infections. Future Virol. 2011;6:451–463.
Asthana AK, Lubel JS. Reactivation of latent viruses after treatment with biological therapies. Virus Adapt Treat. 2014;6:1–10.
Lopez-Serrano P, de la Fuente-Briongos E, Carrera- Alonso E, Perez-Calle JL, et al. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539–547.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Alexanian, D., Birg, A., Volpicelli, N. et al. Latent Hepatitis Virus Reactivation Due to Drug Reaction: DRESSed to Kill?. Dig Dis Sci 63, 1143–1147 (2018). https://doi.org/10.1007/s10620-018-5028-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5028-1